Article

FDA Approves Generic Medication for Muscle Relaxation, Tracheal Intubation

The new product is therapeutically equivalent to Pfizer’s Quelicin.

Amphastar Pharmaceuticals has received FDA approval for succinylcholine chloride injection USP, 200 mg/10mL multiple-dose vials as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

The new product is therapeutically equivalent to Pfizer’s Quelicin. According to Amphastar, IQVIA data showed that succinylocholine chloride injection USP, 200 mg/10 mL made approximately $75 million in United States market annual sales for the 12 months prior to March 31, 2020.

REFERENCE

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial [news release]. Amphastar Pharmaceuticals; June 9, 2020. http://ir.amphastar.com/news-releases/news-release-details/amphastar-pharmaceuticals-inc-receives-fda-approval. Accessed June 9, 2020.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Asthma COPD Breath Nebulizer And Mask Given By Doctor Or Nurse - Image credit: Angelov | stock.adobe.com
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com